-
18 December 2019
-
18 December 2019
Ipsen Announces Departure of David Meek as Chief Executive Officer
PARIS, France, 18 December 2019 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced that David Meek has resigned as the company’s Chief Executive Officer and will step down from the Board of Directors, effective December 31, 2019, to pursue another p...
-
06 December 2019
-
06 December 2019
Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies
PARIS, France, 6 December 2019 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following discussions with the U.S. Food and Drug Administration (FDA), that a partial clinical hold effective immediately, for the pediatric population under the age o...
-
26 September 2019
-
26 September 2019
Ipsen showcases studies at the ESMO 2019 Congress highlighting progress in new approaches for difficult-to-treat cancers
Presentations demonstrate promising advances for the treatment of advanced hepatocellular carcinoma, metastatic pancreatic cancer and neuroendocrine tumors...
-
05 November 2019
-
05 November 2019
Proposed reclassification of Ipsen shares held by Mayroy
Mayroy files a request with the AMF for a waiver to the obligationto file a public offer...
-
25 February 2019
-
25 February 2019
-
18 April 2019
-
18 April 2019
-
12 June 2019
-
12 June 2019
Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years
Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl® for the treatment of certain urological, gynecological and pediatric conditions...
-
04 July 2018
-
04 July 2018